Epithalon Reconstitution Calculator
No human trial has ever established a dose for epithalon. The curated corpus behind this page runs to 45 papers and contains zero registered clinical trials, and none of the reports involving people states a dose, a route, a schedule or a sample size, so this page publishes no dosing range at all. Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, built as the short-peptide analogue of Epithalamin, a peptide complex extracted from the pineal gland by a St Petersburg research group. It is sold as a lyophilised powder that has to be reconstituted with bacteriostatic water before injection, and because no approved product exists, the volume of water added is the only thing setting the concentration. That is all the calculator below does: it converts a vial size and a mixing volume into mg/ml and U-100 syringe units. That is arithmetic about a vial, not a statement about what to inject.
Curated by Dosavy from published literature and regulator labels. Published 11 September 2026, last reviewed 11 September 2026. No clinician reviews this page.
No established human dose
No human trial has established a dose for Epithalon. There is no evidence-based dose to give, and this page does not give one.
The calculator below converts a vial size and a mixing volume into a concentration. That is arithmetic about the vial, not a recommendation about what to inject.
Enter a target dose above to see the draw.
What the evidence says
No human dosing range can be cited. The corpus contains 45 papers and zero registered clinical trials. Human-involving reports do exist, which is why evidence_level is limited_human rather than animal_only: a controlled clinical report of epitalon in degenerative retinal disease claiming a positive clinical effect in 90% of cases (PMID 12195242), chromatin effects measured in leukocytes from subjects aged 75-88 (PMID 15085253), and normalisation of the nocturnal melatonin rhythm described in elderly people alongside old monkeys (PMID 17969590). None of them states a dose, a route, a schedule or a sample size in the retrieved record, so none can back a dosing range. The remainder of the corpus is cell culture, rodent, chicken and monkey work, which per the sourcing standard backs mechanism only. The 5-10 mg daily figure that appears everywhere online has no published human study behind it, and one operator in the practice set dissents at 2 mg/day, recorded in community_practice for exactly that reason.
Epithalon at a glance
- Category
- Longevity
- Half-life
- Not established
- Routes
- Subcutaneous, Intramuscular
- Regulatory status
- Research use only
- Also sold as
- Epithalon, Epitalon, epithalone, AEDG peptide, Ala-Glu-Asp-Gly, Epithalamin (related preparation)
Mechanism
Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly (AEDG), designed as the short-peptide analogue of Epithalamin, a peptide complex extracted from the pineal gland by Vladimir Khavinson's group in St Petersburg. The proposed mechanism is epigenetic: the tetrapeptide is short enough to enter cells and the nucleus, bind directly to double-stranded DNA and to histones H1/3 and H1/6, decondense heterochromatin, and thereby de-repress genes silenced by age-related chromatin condensation (PMIDs 16705247, 15990728, 32019204). Downstream of that, epithalon has been reported to induce hTERT expression and telomerase activity with telomere elongation in cultured human somatic cells, allowing fetal fibroblasts to pass the Hayflick limit by about ten extra divisions (PMIDs 12937682, 15455129), a finding partially reproduced in 2025 across normal and cancer human cell lines (PMID 40908429). A separate line of work reports restoration of the nocturnal melatonin rhythm in aged monkeys and elderly people (PMIDs 14743609, 17969590). Note that this entire body of work originates from essentially one research group and its collaborators, and the strongest results are in cell culture, not in people.
Reconstitution
Sold as a lyophilised powder requiring reconstitution with bacteriostatic water before injection. No approved product, no label reconstitution instructions, and no established concentration exist. Anything a vendor states is the vendor's own convention.
Storage
Supplied by research-chemical vendors as a lyophilised powder. There is no label and no manufacturer's stability data for any product sold for human use; general peptide practice is to keep the sealed lyophilised vial refrigerated and protected from light, and to refrigerate reconstituted solution and use it within a short window. Treat all of this as vendor convention, not as validated stability information.
Frequency in practice
No trial-established frequency exists. Vendors and protocol sites uniformly describe a daily injection given as a short pulsed course of 10-20 days, repeated one to three times a year.
Regulatory
Not approved as a drug in the United States, the EU or Switzerland, and there is no FDA label. It is sold as a research chemical and by longevity-protocol vendors. Its origin is Soviet and Russian gerontology research; the related pineal extract Epithalamin was used clinically in Russia, but Epithalon the synthetic tetrapeptide has no Western marketing authorisation and no registered clinical trial appears in this packet.
What to know before anything else
Epithalon is not approved for human use anywhere in the West. It is sold as a research chemical, and buying it does not mean anyone has established that it is safe or effective in people.
No human dose has ever been published. Every number circulating, including the 5-10 mg daily course everyone repeats, comes from vendors and protocol sites, not from a trial, and no study has compared one dose with another in humans.
The evidence base is unusually narrow. Nearly all of it comes from one Russian research group, much of it published in Russian-language journals, and the strongest results (telomerase induction, telomere elongation, passing the Hayflick limit) are in cultured cells, not in living people. No independent Western group has replicated the human claims.
Telomerase induction is not an unambiguously good thing. The mechanism epithalon is sold for (upregulating hTERT and lengthening telomeres) is the same mechanism cancer cells exploit for unlimited division, and the 2025 cell-line study found telomere extension in breast cancer lines via alternative lengthening of telomeres. Nobody has established what this means for a person with an undetected malignancy.
There is no human safety data of any kind: no published adverse event profile, no dose-limiting toxicity, no drug interaction study, no data in pregnancy, and nothing on long-term or repeated annual courses.
Research-chemical supply carries its own risks independent of the molecule: no identity, purity, endotoxin or sterility guarantee, and lyophilised vials sold 'not for human consumption' are not manufactured to injectable standards.
Epithalon questions
Is there an established human dose for epithalon?
No. There is no FDA label, no registered clinical trial, and no paper in the curated corpus that states a human dose, which is why this page shows no range. The milligram course that circulates on vendor sites and protocol pages has no published human study behind it, and no study has ever compared one dose against another in people. The sellers do not even agree with each other, which is what a number with no evidence under it looks like.
What human studies of epithalon actually exist?
Three reports involve people, which is why this record is graded as limited human evidence rather than animal only. A controlled clinical report in degenerative retinal disease claimed a positive clinical effect in 90% of cases (PMID 12195242). Chromatin effects were measured in leukocytes taken from subjects aged 75 to 88 (PMID 15085253). Normalisation of the nocturnal melatonin rhythm has been described in elderly people alongside old monkeys (PMID 17969590). None of the three states a dose, a route, a schedule or a sample size in the retrieved record, so none of them can support a dosing range.
Does epithalon actually lengthen telomeres?
In cell culture, which is not the same claim. Epithalon has been reported to induce hTERT expression and telomerase activity with telomere elongation in cultured human somatic cells, allowing fetal fibroblasts to pass the Hayflick limit by about ten extra divisions (PMIDs 12937682, 15455129), and that finding was partially reproduced in 2025 across normal and cancer human cell lines (PMID 40908429). The proposed mechanism is epigenetic: the tetrapeptide is short enough to enter the cell and the nucleus, bind directly to double-stranded DNA and to histones, and decondense heterochromatin, de-repressing genes silenced by age-related chromatin condensation. None of that has been shown to happen in a living person.
Is inducing telomerase safe?
Nobody knows, and the question is not rhetorical. The mechanism epithalon is sold for, upregulating hTERT and lengthening telomeres, is the same mechanism cancer cells exploit for unlimited division, and the 2025 cell-line study found telomere extension in breast cancer lines through alternative lengthening of telomeres. What that means for a person carrying an undetected malignancy has never been established. There is no human safety data of any kind either: no published adverse event profile, no dose-limiting toxicity, no drug interaction study, nothing in pregnancy, and nothing on repeated annual courses.
Why is the epithalon evidence base described as narrow?
Because nearly all of it comes from one Russian research group and its collaborators, much of it published in Russian-language journals, and no independent Western group has replicated the human claims. The strongest results are the cell-culture ones. That combination, a single originating group and results that are strongest furthest from a living person, is what nobody outside that group has yet put to the test.
Is epithalon legal, and is it approved anywhere?
It is not approved as a drug in the United States, the European Union or Switzerland, and there is no FDA label for it. It is sold as a research chemical and by longevity-protocol vendors. Its origin is Soviet and Russian gerontology research, and the related pineal extract Epithalamin was used clinically in Russia, but epithalon the synthetic tetrapeptide holds no Western marketing authorisation and no registered clinical trial appears in the curated packet.
How is an epithalon vial mixed and stored?
There is no approved product, so there are no label reconstitution instructions and no established concentration. Anything a vendor states is that vendor's own convention, including the storage advice and the expiry date printed on the vial: no manufacturer stability data exists for material sold for human use. Research-chemical supply carries its own risks independent of the molecule, with no identity, purity, endotoxin or sterility guarantee. This record also holds no half-life and no reviewed interactions for epithalon, so neither its clearance nor its behaviour alongside anything else is something this page can state.
The rest of the math
- Reconstitution calculatorThe full version of the tool above, with syringe barrel sizes and IU conversion.
- Vial longevityHow many doses a vial holds and the date it runs out.
- Cost per doseVial price against doses drawn, so two vial sizes can be compared honestly.
- Half-life and decayFirst-order clearance, time to steady state, and what remains at a given hour.
Same class as Epithalon
You worked out the draw. Now log this dose.
A calculator answers once and forgets. Dosavy keeps the concentration you mixed, the doses you actually took, and a reminder for the next one, with the same evidence labels you see on this page.